Kamada Ltd.
Kibbutz Beit Kama M.P.
Negev
85325
Tel: 07-991-2082
Fax: 07-991-2083
252 articles about Kamada Ltd.
-
Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability
3/6/2024
Kamada Ltd. announced financial results for the three months and year ended December 31, 2023.
-
Kamada Issues 2024 CEO Letter to Shareholders
3/6/2024
Kamada Ltd., a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, issued a Letter to Shareholders from Amir London, Chief Executive Officer.
-
Kamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024Company to Host Conference Call at 8:30am ET
2/28/2024
Kamada Ltd. announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2023, as well as provide 2024 financial guidance, prior to the open of the U.S. financial markets on Wednesday, March 6, 2024.
-
Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years
12/6/2023
Kamada Ltd. announced the execution of a binding memorandum of understanding with Kedrion for the amendment and extension of the KEDRAB® U.S. distribution agreement between the parties.
-
Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance
11/13/2023
Kamada Ltd. announced financial results for the three and nine months ended September 30, 2023.
-
Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023
11/8/2023
Kamada Ltd. today announced that it will release financial results for the third quarter and first nine months ended September 30, 2023, prior to the open of the U.S. financial markets on Monday, November 13, 2023.
-
Kamada Announces Recent Achievements with CYTOGAM® including Availability of Product Manufactured by the Company for U.S Commercial Sale and Presentation of New Clinical Data
10/16/2023
Kamada Ltd. announced multiple recent achievements related to CYTOGAM®, which is indicated for the prophylaxis of cytomegalovirus disease associated with transplantation of kidney, lung, liver, pancreas and heart, and is the sole U.S. Food and Drug Administration approved immunoglobulin product for this indication.
-
Kamada Provides Corporate Update on its Israel Operations
10/10/2023
Kamada Ltd. today announced that while circumstances in Israel are evolving, the Company continues to conduct its business operations in Israel with no effect on business continuity, and its global supply of products is not expected to be interrupted.
-
Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds
8/30/2023
Kamada Ltd. announced shareholder approval and planned closing of the previously announced $60 million private placement with FIMI Opportunity Funds, the leading private equity firm in Israel and a large existing Kamada shareholder.
-
Kamada to Announce Second Quarter and First Half Ended June 30, 2023 Financial Results and Host Conference Call on August 16, 2023
8/9/2023
Kamada Ltd. today announced that it will release financial results for the second quarter and first half ended June 30, 2023, prior to the open of the U.S. financial markets on Wednesday, August 16, 2023.
-
Kamada Announces Kedrion Exercised its Option for Two-Year Extension of KEDRAB® Distribution Agreement in the U.S.
7/12/2023
Kamada Ltd. today announced that Kedrion has exercised its option to extend the distribution agreement between the parties in the U.S. for KEDRAB® (Rabies Immune Globulin [Human]), which is indicated for passive, transient post-exposure prophylaxis (PEP) of rabies infection to persons of all ages when given immediately after contact with a rabid or possibly rabid animal.
-
Kamada Reports Strong First Quarter 2023 Financial Results; Reiterates Revenue and Profitability Guidance
5/24/2023
Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company, with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for three months ended March 31, 2023.
-
Kamada to Announce First Quarter 2023 Financial Results and Host Conference Call on May 24, 2023
5/17/2023
Kamada Ltd. today announced that it will release financial results for the first quarter ended March 31, 2023, prior to the open of the U.S. financial markets on Wednesday, May 24, 2023.
-
Kamada Announces U.S. FDA Approval of its Application to Manufacture CYTOGAM® at the Company’s Facility in Israel
5/3/2023
Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has approved its application to manufacture CYTOGAM® (Cytomegalovirus Immune Globulin Intravenous [Human]) (CMV-IGIV) at the Company’s facility in Beit Kama, Israel.
-
Kamada Reports Strong Fiscal Year and Fourth Quarter 2022 Financial Results, and Provides 2023 Guidance Representing Significant Profitability Growth
3/15/2023
Kamada Ltd. today announced financial results for the 12 and three months ended December 31, 2022.
-
Kamada Issues 2023 CEO Letter to Shareholders
3/15/2023
Kamada Ltd. today issued a Letter to Shareholders from Amir London, Chief Executive Officer.
-
Kamada to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 15, 2023
3/9/2023
Kamada Ltd. today announced that it will release financial results for the fourth quarter and full year ended December 31, 2022, prior to the open of the U.S. financial markets on Wednesday, March 15, 2023.
-
Kamada Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM® at the Company’s Facility in Israel
1/4/2023
Kamada Ltd. today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) to manufacture CYTOGAM® (Cytomegalovirus Immune Globulin Intravenous [Human]) (CMV-IGIV) at its facility in Beit Kama, Israel.
-
Kamada Announces Planned Transition of Chief Financial Officer
12/19/2022
Kamada Ltd. today announced that its Chief Financial Officer (CFO), Chaime Orlev, will transition out of his role to pursue other opportunities, effective March 15, 2023.
-
Kamada Reports Strong Third Quarter Financial Results Demonstrating Successful Strategic Transition and Reiterates 2022 Financial Guidance
11/22/2022
Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced financial results for the three and nine months ended September 30, 2022.